Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Amaresh K Ranjan

Amaresh K Ranjan

Icahn School of Medicine at Mount Sinai, USA

Title: Serum transcripts of hsp27b1, hsp27b2 and CD133 predict the endothelial damage in diabetes

Biography

Biography: Amaresh K Ranjan

Abstract

Vascular endothelial cell damage/dysfunction is known to be associated with the common etiology of morbidity and mortality in diabetic conditions. However, suitable markers of endothelial damage in diabetes are still required to be discovered. We studied endothelial damage in diabetes by using proteomics and genomics approaches. Human vascular endothelial cells were subjected to in vitro normoglycemia or hyperglycemia. Expression of endothelial specific genes responsible to regulate atherosclerosis, immune response, migration and adhesion were found affected in hyperglycemia. Proteomics studies by using 2D gel electrophoresis and tandem mass spectrometry indicated modulation of 12 new proteins including Hsp27b1, Macf1, Vim, Ckm, Tcp, Prv, Atm, Vinc, Smthln, Pmpcb, Nebl and Tcf20. Moreover, we observed higher transcript abundance of Hsp27b1, Hsp27b2, Ckm, Prv, Vinc, PMPCB and Tcf 20 in both type 1 and type 2 diabetic patients’ serum samples compared to that of non-diabetic (control) patients. We selected Hsp27b1, Hsp27b2 and Ckm to screen a larger cohort of diabetic patients (n=20) for their transcript abundance. Significantly higher transcript abundance of Hsp27b1 (p≤0.01) and Hsp27b2 (p≤0.001) along with CD133 (an endothelial specific marker) (p≤0.05) were observed in diabetic patients’ sera. Thus, our present study shows potential of hsp27b1, hsp27b2 and CD133 transcripts as a combinatorial biomarker of endothelial damage in diabetes. These biomarkers may help to detect or develop a therapy to reverse the pathophysiological changes responsible for secondary complications of diabetes.